Succinylated Human Serum Albumin (Suc-HSA) for HIV-1 Infection

This study has been completed.
Sponsor:
Collaborators:
University Medical Centre Groningen
Sanquin
Information provided by:
International Antiviral Therapy Evaluation Center
ClinicalTrials.gov Identifier:
NCT00128063
First received: August 8, 2005
Last updated: April 23, 2007
Last verified: April 2007

August 8, 2005
April 23, 2007
August 2005
Not Provided
To evaluate the pharmacokinetic behavior of Suc-HSA after consecutive daily i.v. doses.
Same as current
Complete list of historical versions of study NCT00128063 on ClinicalTrials.gov Archive Site
To evaluate the safety and tolerability and the antiretroviral and immunological effects of consecutive daily i.v. doses of Suc-HSA.
Same as current
Not Provided
Not Provided
 
Succinylated Human Serum Albumin (Suc-HSA) for HIV-1 Infection
A Phase 1 & 2, Randomized Open-Label Study to Evaluate the Pharmacokinetics, Safety and Antiretroviral Activity of Succinylated Human Serum Albumin (Suc-HSA) in Treatment Naïve HIV-1 Infected Subjects

The primary objective of the study is to evaluate the pharmacokinetic behavior of Suc-HSA after consecutive daily intravenous (i.v.) doses. The secondary objectives are to evaluate the safety and tolerability and the antiretroviral and immunological effects of consecutive daily i.v. doses of Suc-HSA.

This is a single centre, single arm study. Subjects will receive 5 consecutive daily doses of Suc-HSA at a dose of 10 mg/kg on days 0, 1, 2, 3 and 4 on the Special Investigation Unit (SIU), with a safety follow up on the SIU for 4 hours on day 1 and 2 hours on the next days. There will be follow-up visits on week 1, 2, 4 and 12. Standard safety parameters (physical examination, clinical symptoms, laboratory hematology and biochemistry) will be followed until week 12. Plasma HIV-1 RNA and CD4+/CD8+ cell counts will be assessed at every visit. Plasma drug levels (trough and peak) will be measured from baseline until week 2.

6 patients will be included in this study as described in this protocol amendment.

Eligible subjects are chronic HIV-1 infected patients who have never been treated with antiretroviral treatment and for whom there is no need to start antiretroviral treatment.

Test Product: Suc-HSA, a candidate HIV-1 fusion inhibitor.

Duration of treatment: 5 days

Criteria for evaluation:

  • Safety: symptoms, signs at physical examination, standard hematology and chemistry laboratory parameters- Efficacy: changes in plasma HIV-1 RNA and CD4+ T cell count
  • Pharmacokinetics: plasma levels of Suc-HSA: Cmin, Cmax and AUC
Interventional
Phase 1
Phase 2
Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
HIV Infections
Drug: succinylated human serum albumin
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
6
June 2006
Not Provided

Inclusion Criteria:

  1. Patient is ≥ 18 years of age;
  2. Voluntarily signed informed consent;
  3. Patient has a proven HIV-1 infection (with positive antibodies against HIV-1 and a detectable plasma HIV-1 RNA);
  4. Patient is HIV-1 treatment naïve;
  5. CD4+ T-cell count ≥ 350 x 10^6/L;
  6. Plasma HIV-1 RNA level at screening visit of at least 5.000 copies/ml, and not varying more than ± 0.5 log10 copies during the preceding 6 month period;
  7. Patient was participant in part 1 of the original Suc-HSA study (protocol no. 2003-002, version 2.4, dated 18 November 2003) and the administration of Suc-HSA occurred more than 8 weeks ago, OR patient was not participant in this study;
  8. Patient is one of the following:

    • not heterosexually active, OR
    • a heterosexually active female, agreeing to use an effective method of contraception with her partner (combined oral contraceptive pill; injectable contraceptive; intrauterine contraceptive device (IUCD); consistent use of condoms if using these; physiological or anatomical sterility in herself or her partner) from 14 days prior to the first administration of study medication until 4 months after the last, and willing to undergo urine pregnancy tests prior to the first and last administration, OR
    • a heterosexually active male, agreeing to use an effective method of contraception with his partner from the day of the first administration until 4 months after the last administration.

Exclusion Criteria:

  1. History of an AIDS defining event;
  2. Use of antiretroviral or immunomodulatory therapy;
  3. Any reason to start antiretroviral therapy at the time of enrolment or which is expected to occur during the course of the study at the time of enrolment;
  4. Presence of active, replicating hepatitis B and/or C virus co-infection;
  5. ASAT and/or ALAT > 3 times upper limit of normal (ULN) (AIDS Clinical Trials Group [ACTG] toxicity scale);
  6. Serum creatinine measuring > 1.5 x ULN;
  7. Total bilirubin > 2x ULN;
  8. Neutropenia (absolute neutrophil count < 1000/mm3);
  9. Presence of any clinically significant disease or findings during screening, that in the opinion of the investigator could compromise the safety of the subject;
  10. Patient is female and (willing to become) pregnant or breast-feeding;
  11. Any other condition which, in the opinion of the investigator, may interfere with the evaluation of the study objectives.
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
Netherlands
 
NCT00128063
04-IAT-0047
Yes
Not Provided
International Antiviral Therapy Evaluation Center
  • University Medical Centre Groningen
  • Sanquin
Study Chair: Joep MA Lange, MD PhD Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Principal Investigator: Jan Prins, MD PhD Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
International Antiviral Therapy Evaluation Center
April 2007

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP